Relationship Between Serotonin and Brain Response to Social Dominance and Emotion Perception. (SERODOM)
Relationship Between Serotonin and Brain Response to Social Dominance Perception and Emotion: a Combined [11C]DASB-PET/fMRI Study in Humans
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- Hospices Civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- French speaking
- Normal vision
- Age from 18 to 45
- Without psychiatric antecedent
- Without any neurologic antecedent
- Not taking psychotropic or anxiolytic drugs
- Having health insurance coverage
Exclusion Criteria:
- The subject does not wish to be notified of any anomalies detected during MRI
- Subjects suffering from claustrophobia
- Subjects carrying magnetic metal objects that cannot be removed as cochlear implant, surgical clips, piercings, pacemakers, mechanical valves
- Subjects participating in a clinical trial or being in a period of exclusion from a previous clinical trial
- Person under guardianship or curatorship or deprived of liberty or in emergencies
- Taking unauthorized treatment in the month before the completion of the review
- Person whose physical or mental condition does not allow him to pass the test study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Dominance
Healthy subjects
|
fMRI scan include MR sequences: BOLD and fMRI.
The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of [11C]DASB bolus.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
level of Blood-Oxygen-Level Dependent (BOLD) signal
Time Frame: at day 0
|
The BOLD signal will be measured using a MRI scanner, and simultaneously we will record the level of serotonin transporter with [11C]DASB marker of the serotonin transmission, using a PET signal.
We will use the Scatchard method in order to determine the level of [11C]DASB bonded to the transporter.
Our reference region will be the cerebellum.
|
at day 0
|
|
level of serotonin transporter
Time Frame: at day 0
|
The BOLD signal will be measured using a MRI scanner, and simultaneously we will record the level of serotonin transporter with [11C]DASB marker of the serotonin transmission, using a PET signal.
We will use the Scatchard method in order to determine the level of [11C]DASB bonded to the transporter.
Our reference region will be the cerebellum.
|
at day 0
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Behavioral assessment
Time Frame: at day 0
|
During the entire scanner, subjects will be ask to perform a behavioral task.
Their responses will be analyzed.
|
at day 0
|
|
Testosterone Blood level
Time Frame: after the scan session at day 0
|
The testosterone will be measured on a blood sample.
|
after the scan session at day 0
|
|
Cortisol Blood level
Time Frame: after the scan session at day 0
|
The cortisol will be measured on a blood sample (prelevated at same time than testosterone).
|
after the scan session at day 0
|
|
SLC6A4 genotyping
Time Frame: at day 0
|
The genotyping of this gene (SLC6A4) will be realized on a sample of saliva.
|
at day 0
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christian SCHEIBER, Hospices Civils de Lyon - CNRS UMR 5229
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 69HCL16_0014
- 2016-A01588-43 (OTHER: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.